# US 2023/0406813 A1 · P62-zz chemical inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406813 A1
- Document ID: US20230406813A1
- Status: Published application
- Kind: A1
- Application number: 18/238,830
- Filed: 2023-08-28
- Published: 2023-12-21
- Earliest claimed: 2011-08-08
- Assignees: ID4Pharma, LLC
- Applicants: Id4Pharma, LLC
- Inventors: Xiang-Qun XIE
- Web page: https://patentgrep.com/patent/US20230406813A1

## CPC

- C07C 229/36: with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/15: Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/351: not condensed with another ring
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07C 211/50: with at least two amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C 217/58: with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C07C 217/76: having amino groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C 219/06: having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C 229/14: to carbon atoms of carbon skeletons containing rings
- C07C 235/48: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 249/16: of hydrazones
- C07C 251/76: to carbon atoms of a saturated carbon skeleton
- C07C 317/34: having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07D 241/44: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D 309/32: having two double bonds between ring members or between ring members and non-ring members
- C07D 309/40: Oxygen atoms attached in positions 3 and 4, e.g. maltol
- C07D 475/08: with a nitrogen atom directly attached in position 2
- C07D 487/04: Ortho-condensed systems
- C12N 5/0693: {Tumour cells; Cancer cells}
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.

## Claims

### Claim 1

A method for treating a p62-mediated disease in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound of structural Formula I:
or a pharmaceutically acceptable salt or ester thereof, wherein
Ar is an arylene or heteroarylene;
R1 has a structure of:
wherein W is an alkanediyl, alkenediyl, a carbonyl, or a combination thereof;
X is —NR5—, wherein R5 is H or an alkyl, or —O—; and
Y is a hydroxyalkyl, an aminoalkyl, or a carboxylalkyl;
each R2 is the same or different and has a structure of:
wherein Z is —NR6—, wherein R6 is H or an alkyl, —O—, —S—, or —CH2—;
Z1 is (—CH2—)m wherein m is 0 to 5, or an alkenediyl having 2 to 6 carbon atoms;
Cy is a 3-8-membered cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring; and
each R4 is the same or different and is selected from hydroxy, halogen, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, or amino; and c is 0 to 5; and
each R3 is the same or different and is selected from hydrogen, hydroxy, halogen, —CN, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, amino, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or a nitro, wherein a is 0 to 5, and b is 0 to 3.

### Claim 2 (depends on 1)

The method of claim 1, wherein b is 0.

### Claim 3 (depends on 2)

The method of claim 2, wherein W is —CH2.

### Claim 4 (depends on 2)

The method of claim 2, wherein:
X is —NR5; and
R5 is H.

### Claim 5 (depends on 2)

The method of claim 2, wherein Cy is phenyl.

### Claim 6 (depends on 2)

The method of claim 2, wherein a is 1 or 2.

### Claim 7 (depends on 2)

The method of claim 2, wherein:
R4 is alkyl or halogen; and
c is 1 or 2.

### Claim 8 (depends on 7)

The method of claim 7, wherein R4 is methyl.

### Claim 9 (depends on 7)

The method of claim 7, wherein R4 is fluorine.

### Claim 10 (depends on 2)

The method of claim 2, wherein R2 is

### Claim 11 (depends on 2)

The method of claim 2, wherein Z is —O—.

### Claim 12 (depends on 2)

The method of claim 2, wherein:
Z1 is (—CH2—)m; and
m is 1.

### Claim 13 (depends on 2)

The method of claim 2, wherein Ar is a benzenetriyl.

### Claim 14 (depends on 2)

The method of claim 2, wherein Y is hydroxyalkyl.

### Claim 15 (depends on 2)

The method of claim 2, wherein Y is aminoalkyl.

### Claim 16 (depends on 15)

The method of claim 15, wherein the compound is selected from the group consisting of

### Claim 17 (depends on 2)

The method of claim 2, wherein Y is carboxylalkyl.

### Claim 18 (depends on 17)

The method of claim 17, wherein the compound is

### Claim 19 (depends on 2)

The method of claim 2, wherein:
Y is R1;
R1 is —CH2—X—(CH2)2—R11;
X is NH or O; and
R11 is hydroxy, carboxyl, substituted carboxyl or amino.

### Claim 20 (depends on 19)

The method of claim 19, wherein X is NH and R11 is amino.

### Claim 21 (depends on 20)

The method of claim 20, wherein the compound is selected from the group consisting of:

### Claim 22 (depends on 19)

The method of claim 19, wherein X is NH and R11 is hydroxyl.

### Claim 23 (depends on 22)

The method of claim 22, wherein the compound is selected from the group consisting of

### Claim 24 (depends on 1)

The method of claim 1, wherein the p62-mediated disease is multiple myeloma.

### Claim 25 (depends on 1)

The method of claim 1, further comprising inhibiting osteoclastogenesis and/or reducing osteoclast activation.

### Claim 26 (depends on 1)

The method of claim 1, wherein the p62-mediated disease is drug-resistant multiple myeloma.

### Claim 27 (depends on 1)

The method of claim 1, further comprising co-administering the compound with at least one anti-cancer agent.

### Claim 28

A method of modulating p62 activity in stromal cells, comprising contacting stromal cells with a compound of structural Formula I or a pharmaceutically acceptable salt or ester thereof.

### Claim 29

A method of inhibiting multiple myeloma cell growth, comprising contacting multiple myeloma cells with at least one p62-ZZ inhibitor compound of structural Formula I or a pharmaceutically acceptable salt or ester thereof.

### Claim 30

A compound of structural Formula I:
or a pharmaceutically acceptable salt or ester thereof, wherein:
Ar is an arylene or heteroarylene;
R1 has a structure of:
wherein W is an alkanediyl, alkenediyl, a carbonyl, or a combination thereof;
X is —NR5—, wherein R5 is H or an alkyl, or —O—; and
Y is a hydroxyalkyl, an aminoalkyl, or a carboxylalkyl;
each R2 is the same or different and has a structure of:
wherein Z is —NR6—, wherein R6 is H or an alkyl, —O—, —S—, or —CH2—;
Z1 is (—CH2—)m wherein m is 0 to 5, or an alkenediyl having 2 to 6 carbon atoms;
Cy is a 3-8-membered cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring; and
each R4 is the same or different and is selected from hydroxy, halogen, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, or amino; and c is 0 to 5; and
each R3 is the same or different and is selected from hydrogen, hydroxy, halogen, —CN, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, amino, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or a nitro, wherein a is 0 to 5, and b is 0 to 3, provided that the compound is not:

### Claim 31 (depends on 30)

The compound of claim 30, wherein b is 0.

### Claim 32 (depends on 31)

The compound of claim 31, wherein W is —CH2.

### Claim 33 (depends on 31)

The compound of claim 31, wherein:
X is —NR5; and
R5 is H.

### Claim 34 (depends on 31)

The compound of claim 31, wherein Cy is phenyl.

### Claim 35 (depends on 31)

The compound of claim 31, wherein a is 1 or 2.

### Claim 36 (depends on 31)

The compound of claim 31, wherein:
R4 is alkyl or halogen; and
c is 1 or 2.

### Claim 37 (depends on 36)

The compound of claim 36, wherein R4 is methyl.

### Claim 38 (depends on 36)

The compound of claim 36, wherein R4 is fluorine.

### Claim 39 (depends on 31)

The compound of claim 31, wherein R2 is

### Claim 40 (depends on 31)

The compound of claim 31, wherein Z is —O—.

### Claim 41 (depends on 31)

The compound of claim 31, wherein:
Z1 is (—CH2—)m; and
m is 1.

### Claim 42 (depends on 31)

The compound of claim 31, wherein Ar is a benzenetriyl.

### Claim 43 (depends on 31)

The compound of claim 31, wherein Y is hydroxyalkyl.

### Claim 44 (depends on 31)

The compound of claim 31, wherein Y is aminoalkyl.

### Claim 45 (depends on 44)

The compound of claim 44, wherein the compound is selected from the group consisting of

### Claim 46 (depends on 31)

The compound of claim 31, wherein Y is carboxylalkyl.

### Claim 47 (depends on 46)

The compound of claim 46, wherein the compound is

### Claim 48 (depends on 31)

The compound of claim 31, wherein:
Y is R1;
R1 is —CH2—X—(CH2)2—R11;
X is NH or O; and
R11 is hydroxy, carboxyl, substituted carboxyl or amino.

### Claim 49 (depends on 48)

The compound of claim 48, wherein X is NH and R11 is amino.

### Claim 50 (depends on 49)

The compound of claim 49, wherein the compound is selected from the group consisting of:

### Claim 51 (depends on 48)

The compound of claim 48, wherein X is NH and R11 is hydroxyl.

### Claim 52 (depends on 51)

The compound of claim 51, wherein the compound is selected from the group consisting of

### Claim 53

A pharmaceutical composition comprising at least one pharmaceutically acceptable additive, and compound, or a pharmaceutically acceptable salt or ester thereof, of structural Formula I.
